Adaptimmune Therapeutics plc - Asset Resilience Ratio

Latest as of June 2025: 0.00%

Adaptimmune Therapeutics plc (473A) has an Asset Resilience Ratio of 0.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 473A current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

€0.00

≈ $0.00 USD Cash + Short-term Investments

Total Assets

€130.63 Million

≈ $152.72 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Adaptimmune Therapeutics plc's Asset Resilience Ratio has changed over time. See Adaptimmune Therapeutics plc shareholders equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Adaptimmune Therapeutics plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 473A market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€0.00	0%
Total Liquid Assets	€0.00	0.00%

Asset Resilience Insights

Limited Liquidity: Adaptimmune Therapeutics plc maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company maintains a balanced mix of cash and short-term investments.

Adaptimmune Therapeutics plc Industry Peers by Asset Resilience Ratio

Compare Adaptimmune Therapeutics plc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
No industry peers found with asset resilience data.

Annual Asset Resilience Ratio for Adaptimmune Therapeutics plc (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Adaptimmune Therapeutics plc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	24.58%	€60.47 Million ≈ $70.69 Million	€245.96 Million ≈ $287.56 Million	+23.54pp
2023-12-31	1.04%	€2.95 Million ≈ $3.45 Million	€282.62 Million ≈ $330.41 Million	-28.32pp
2022-12-31	29.36%	€96.57 Million ≈ $112.90 Million	€328.92 Million ≈ $384.54 Million	-17.41pp
2021-12-31	46.78%	€219.63 Million ≈ $256.77 Million	€469.55 Million ≈ $548.95 Million	-22.23pp
2020-12-31	69.01%	€311.33 Million ≈ $363.98 Million	€451.14 Million ≈ $527.43 Million	+47.46pp
2019-12-31	21.55%	€39.13 Million ≈ $45.75 Million	€181.54 Million ≈ $212.24 Million	-27.86pp
2018-12-31	49.42%	€136.75 Million ≈ $159.88 Million	€276.74 Million ≈ $323.53 Million	+5.23pp
2017-12-31	44.18%	€124.22 Million ≈ $145.22 Million	€281.15 Million ≈ $328.69 Million	+34.51pp
2016-12-31	9.68%	€22.69 Million ≈ $26.53 Million	€234.51 Million ≈ $274.17 Million	--

pp = percentage points

About Adaptimmune Therapeutics plc

F:473A Germany

Market Cap

$50.20 Million

€42.94 Million EUR

Market Cap Rank

#22430 Global

#1980 in Germany

Share Price

€0.16

Change (1 day)

+6.58%

52-Week Range

€0.03 - €0.41

All Time High

€12.93